JUND and neoplasm: Given the imbalance between the activating and immunoregulatory IRF4/AP1 complexes induced by persistent high expression of IRF4 and AP1 family members in specific contexts, manipulating the composition of the IRF4/AP1 complexes may be a novel therapeutic strategy for overcoming T cell exhaustion and improving anti-tumor potency.